Emergent offers biopharmaceutical companies a strategic and reliable solution to their clinical and commercial supply chain needs. As a committed and reliable CDMO partner, we have the scientific and regulatory compliance experience and cGMP manufacturing capabilities to support complex and challenging programs.
Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies, which began in February 2021.
Lenzilumab™ is currently in a Phase 3 clinical trial evaluating patients hospitalized with COVID-19. Humanigen intends to file for EUA first quarter of 2021.
Recognizes manufacturing facility and processes are in compliance with GMP requirements and readiness to provide commercial aseptic fill/finish services.
Advantages over conventional drug delivery devices, rise in prevalence of COPD and asthma drive the growth of the global aerosol delivery devices market.
Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
Fran L. DeGrazio of West discusses why and how vaccine development is different than drug development and the impacts of COVID-19 on vaccine development.
Emergent BioSolutions, Inc. has launched Singapore operations through EPIC Bio Ltd., a joint venture with Temasek Life Sciences Ventures Ltd. (TLV), to develop, manufacture, and commercialize pandemic influenza vaccines and therapeutics.